Drug intelligence / Profile preview

IFN-Zika

Development stage: Preclinical
Lead developer: Canthevac
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

IFN-Zika is an experimental live-attenuated vaccine candidate being developed by Canthevac for the prevention of Zika virus infection. The vaccine is designed using Canthevac's proprietary Interferon-integrated Vaccine Platform (IVP), which incorporates interferon activity directly into the vaccine construct. This integration is intended to stimulate a robust immune response, including both B-cell and T-cell immunity, while maintaining safety by utilizing interferon's natural antiviral properties to control vaccine replication. IFN-Zika is currently in preclinical development.

Targets

IFNGR1 (Interferon gamma receptor 1)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on IFN-Zika.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IFN-Zika.

Explore the full profile